The burden of chronic rhinosinusitis with nasal polyps

CRS is an inflammatory condition of the upper airways[1]



CT image of a patient with severe CRSwNP[5]

Estimates of global CRS prevalence vary: >10% of the population has been estimated to have CRS based on symptomatic or objective evidence, while the presence of both has produced estimates of **<5%**.[1]

CRS with nasal polyps (CRSwNP) represents **18–30%** of all cases of CRS.[1–3]

CRSwNP is characterized by the presence of nasal polyps and chronic sinonasal inflammation, which can result in symptoms such as:[4]

Nasal congestion | Nasal discharge | Facial pain/pressure | Impaired sense of smell

CRSwNP is characterized by a decreased quality of life, and it places a significant psychological and social burden on patients[6,7]

Food enjoyment | Sleep quality | Confidence | Depression/anxiety

Quality of life can be further reduced for patients with CRSwNP and comorbid asthma.[8]

CRSwNP represents heterogeneous, and often overlapping, endotypes[10]

CRSwNP can be divided into **three endotypes** based on the inflammatory profiles associated with **specific immune cells**, **cytokines**, and **dominant clinical features**:[11]

Type 1	Type 2	Type 3
IFN-γ and IL-12[11]	**IL-4, IL-5, and IL-13**[11]	**IL-17 and IL-22**[11]
ILC1, NK cells, Th1 cells, CD8+ T cells, and M1 macrophages[11]	**ILC2, eosinophils, basophils, mast cells, Th2 cells, and M2 macrophages**[11]	**ILC3, neutrophils, and Th17 cells**[11]
Headache and facial pain[10]	**Loss of sense of smell and comorbid asthma**[10–12]	**Purulent rhinorrhea**[10–12]

- In the US, **Type 2** is the most common endotype of CRSwNP.[11]
- Many patients with CRSwNP have a **mixed endotype**, and ~9% have **no clear endotype**.[10,12b]

Despite medication and surgery, many patients with CRSwNP have uncontrolled disease[16]

In a survey of **437 physicians**, **70%** reported that **OCS** provide only **temporary symptom relief** in CRSwNP.[17]

38% of patients (n=125) experienced **polyp recurrence** 12 months after medical therapy and sinus surgery.[16c]

~80% of patients with CRSwNP (n=212) experienced **inadequately controlled symptoms** within 3 to 5 years after surgery.[18d]

CRSwNP is often associated with asthma[9]

Up to 56% of patients with **CRSwNP** have **comorbid asthma**[9b]

8–21% of patients with **severe asthma** have a history of **nasal polyps**[13,14]

In asthmatic patients, comorbid CRSwNP is associated with increased exacerbation frequency, increased symptom severity, and reduced quality of life.[8,15]

Did you know?

- **NPS** is often used as a primary outcome in clinical trials for CRSwNP.[19]
- NPS uses endoscopy to assess **polyp size** in each nostril, ranging from 0 to 4.[19]
- Total NPS is the sum of the scores for each nostril (0–8); **higher scores indicate more severe disease**.[19]

[a]Patients without a clear endotype are defined as those expressing biomarkers below detection thresholds;[10,12] [b]Range: 5–56%;[9] [c]Medical therapy included, but was not limited to, at least one course of either topical corticosteroids or a course of OCS therapy and at least one course of broad-spectrum or culture-directed antibiotics;[16] [d]Control was assessed using mean total VAS, SNOT-22, and SF-36 scores in patients with CRSwNP 3–5 years after FESS.[18]

CRS, chronic rhinosinusitis; CRSwNP, chronic rhinosinusitis with nasal polyps; CT, computed tomography; EMT, epithelial-mesenchymal transition; FESS, functional endoscopic sinus surgery; IFN, interferon; IL, interleukin; ILC, innate lymphoid cell; NK, natural killer; NPS, nasal polyp score; OCS, oral corticosteroid(s); PRR, pattern recognition receptor; SF-36, Short Form 36-item Health Survey; SNOT-22, Sino-Nasal Outcome Test-22; Th, T helper; tPA, tissue plasminogen activator; TSLP, thymic stromal lymphopoietin; VAS, visual analog scale.

EpiCentral
UNDERSTANDING THE CENTRAL ROLE OF THE EPITHELIUM IN SEVERE ASTHMA AND BEYOND

AMGEN® AstraZeneca

The central role of the epithelium in CRSwNP

The nasal epithelium is significantly altered in CRSwNP and plays a critical role in the disease[20]



Role of epithelial cytokines in CRSwNP

Epithelial cytokines are released in response to environmental irritants, such as allergens, pathogens, and pollutants.[27]



TSLP, **IL-25**, and **IL-33** are increased in nasal mucosal epithelial tissue from patients with CRSwNP compared with controls, with the highest levels observed in eosinophilic CRSwNP.[27]

TSLP, the TSLP receptor, and the IL-33 receptor correlated with increased disease severity and Type 2 inflammation[28]



Disruption of the epithelium augments inflammation and is central to nasal polyp formation:

A Epithelial damage triggers EMT; mesenchymal cells alter inflammatory and remodeling processes.[24,25]

B Epithelial cytokines TSLP and IL-33 drive multiple downstream processes, including mast cell activation and production of IL-4, IL-5, and IL-13.[21]

C Mast cells and basophils drive mucosal edema, resulting in plasma leakage.[21]

D Cross-linked fibrin forms a dense mesh and promotes edema.[21,23]

E Elevated IL-4 and IL-13 suppress the expression of tPA and prevent breakdown of fibrin.[21,26]

Did you know?

CRSwNP and asthma share similar features of **airway remodeling and inflammation**.[29,30]

Fibrosis and matrix deposition[29] | Impaired mucociliary clearance[29] | Immune cell infiltration[29] | Epithelial cytokine production[30] | Impaired epithelial integrity[29]

Their shared pathophysiology and frequent co-occurrence support the concept of **united airways disease**, in which the upper and lower airways are linked anatomically, histologically, and immunologically.[31–33]

1. Sedaghat AR, et al. J Allergy Clin Immunol Pract. 2022;10:1395–1403; 2. Benjamin MR, et al. J Allergy Clin Immunol Pract. 2019;7:1010–1016; 3. Stevens WW, et al. J Allergy Clin Immunol Pract. 2016;4:565–572; 4. Orlandi RR, et al. Int Forum Allergy Rhinol. 2021;11:213–739; 5. Schleimer RP. Annu Rev Pathol. 2017;12:331–357; 6. Bachert C, et al. J Asthma Allergy. 2021;14:127–134; 7. Mullol J, et al. J Allergy Clin Immunol Pract. 2022;10:1434–1453.e9; 8. Laidlaw TM, et al. J Allergy Clin Immunol Pract. 2021;9:1133–1141; 9. Chen S et al. Curr Med Res Opin. 2020;36(11):1897-1911; 10. Hao D, et al. J Inflamm Res. 2022;15:5557-5565; 11. Staudacher AG, et al. Ann Allergy Asthma Immunol. 2020;124:318–325; 12. Stevens WW, et al. J Allergy Clin Immunol Pract. 2019;7:2812-2820.e3; 13. Reddel HK, et al. Eur Respir J. 2021;58:2003927; 14. Scelo G, et al. Ann Allergy Asthma Immunol. 2024;132:42-53; 15. Denlinger LC, et al. Am J Respir Crit Care Med. 2017;195:302–313; 16. DeConde AS, et al. Laryngoscope. 2017;127:550–555; 17. De Corso E, et al. J Pers Med. 2022;12:897; 18. van der Veen J, et al. Allergy. 2017;72:282–290; 19. Gevaert P, et al. Allergy. 2023;78:912–922; 20. Petalas K, et al. Int J Mol Sci. 2023;24:12379; 21. Kato A, et al. J Allergy Clin Immunol. 2022;149:1491–1503; 22. Saitoh T, et al. Rhinology. 2009;47:275–279; 23. Takabayashi T, Schleimer RP. J Allergy Clin Immunol. 2020;145:740–750; 24. Chiarella E, et al. Int J Mol Sci. 2020;21:6878; 25. Wang Y, et al. Sci Rep. 2024;14:2270; 26. Hulse KE, et al. Clin Exp Allergy. 2015;45:328–346; 27. Zhang M, et al. Int Immunopharmacol. 2023;121:110559; 28. Liao B, et al. Allergy. 2015;70:1169–1180; 29. Siddiqui S, et al. J Allergy Clin Immunol. 2023;152:841–857; 30. Patel NN, et al. Int Forum Allergy Rhinol. 2019;9:93–99; 31. De Corso E, et al. J Pers Med. 2022;12:846; 32. Fokkens W, Reitsma S. Otolaryngol Clin North Am. 2023;56:1–10; 33. Jakwerth CA, et al. Cells. 2022;11:1387.

EpiCentral
UNDERSTANDING THE CENTRAL ROLE OF THE EPITHELIUM IN SEVERE ASTHMA AND BEYOND

AMGEN® AstraZeneca